{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:26:46Z","timestamp":1771493206483,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A drug holiday of 3 months does not promote separation of sequestra and is not correlated with treatment outcomes after surgical therapy in osteoporosis patients who receive antiresorptive agents and who have medication-related osteonecrosis of the jaw. Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse effect of antiresorptive agents alone or in combination with immune modulators or antiangiogenic medications, in the absence of radiation exposure to the head and neck region. The effectiveness of surgical treatment for MRONJ has been reported, but the timing of the operation remains controversial. The purpose of this study was to clarify whether preoperative drug holidays of antiresorptive agents promote sequestrum separation and improve treatment outcomes in patients who receive low doses of antiresorptive agents. This retrospective study included 173 patients who received low-dose antiresorptive agents and underwent surgical therapy. The effects of a drug holiday on the separation of sequestra and treatment outcomes were analyzed using logistic and Cox regression analyses. Multivariate analysis revealed that administration of an antiresorptive agent for more than 4\u00a0years, a high number of lymphocytes, and an extensive osteolytic area were significantly correlated with separation of sequestra, but drug holiday did not promote sequestrum separation. Furthermore, a drug holiday of 90, 120 or 180\u00a0days did not show any improvement in treatment outcomes. The drug holiday of the antiresorptive agents for the treatment of MRONJ is unnecessary, and surgical therapy should be performed early.<\/jats:p>","DOI":"10.1038\/s41598-022-15720-7","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T16:04:15Z","timestamp":1657209855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Relationship between drug holiday of the antiresorptive agents and surgical outcome of medication-related osteonecrosis of the jaw in osteoporosis patients"],"prefix":"10.1038","volume":"12","author":[{"given":"Kota","family":"Morishita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4646-587X","authenticated-orcid":false,"given":"Sakiko","family":"Soutome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsunobu","family":"Otsuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misa","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"15720_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J. Oral Maxillofac. Surg. 72, 1938\u20131956. https:\/\/doi.org\/10.1016\/j.joms.2014.04.031 (2014).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"15720_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00774-010-0162-7","volume":"28","author":"T Yoneda","year":"2010","unstructured":"Yoneda, T. et al. Bisphosphonate-related osteonecrosis of the jaw: Position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J. Bone Miner. Metab. 28, 365\u2013383. https:\/\/doi.org\/10.1007\/s00774-010-0162-7 (2010).","journal-title":"J. Bone Miner. Metab."},{"key":"15720_CR3","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.oraloncology.2014.08.016","volume":"50","author":"K Rupel","year":"2014","unstructured":"Rupel, K. et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 50, 1049\u20131057. https:\/\/doi.org\/10.1016\/j.oraloncology.2014.08.016 (2014).","journal-title":"Oral Oncol."},{"key":"15720_CR4","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","volume":"44","author":"R Fliefel","year":"2015","unstructured":"Fliefel, R., Tr\u00f6ltzsch, M., K\u00fchnisch, J., Ehrenfeld, M. & Otto, S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int. J. Oral Maxillofac. Surg. 44, 568\u2013585. https:\/\/doi.org\/10.1016\/j.ijom.2015.01.026 (2015).","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"15720_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan, A. A. et al. International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J. Bone Miner. Res. 30, 3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"15720_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.oraloncology.2010.11.007","volume":"47","author":"P Vescovi","year":"2011","unstructured":"Vescovi, P. et al. Surgery-triggered and non surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol. 47, 191\u2013194. https:\/\/doi.org\/10.1016\/j.oraloncology.2010.11.007 (2011).","journal-title":"Oral Oncol."},{"key":"15720_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00432-010-0953-1","volume":"137","author":"T M\u00facke","year":"2011","unstructured":"M\u00facke, T. et al. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J. Cancer Res. Clin. Oncol. 137, 907\u2013913. https:\/\/doi.org\/10.1007\/s00432-010-0953-1 (2011).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"15720_CR8","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1016\/j.joms.2012.05.019","volume":"70","author":"F Graziani","year":"2012","unstructured":"Graziani, F. et al. Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases. J. Oral Maxillofac. Surg. 70, 2501\u20132507. https:\/\/doi.org\/10.1016\/j.joms.2012.05.019 (2012).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"15720_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1600-0714.2011.01091.x","volume":"41","author":"P Vescovi","year":"2012","unstructured":"Vescovi, P. et al. Bisphosphonates-related osteonecrosis of the jaws: A concise review of the literature and a report of a single-centre experience with 151 patients. J. Oral Pathol. Med. 41, 214\u2013221. https:\/\/doi.org\/10.1111\/j.1600-0714.2011.01091.x (2012).","journal-title":"J. Oral Pathol. Med."},{"key":"15720_CR10","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2012.13605","volume":"142","author":"C Jacobsen","year":"2012","unstructured":"Jacobsen, C., Metzler, P., Obwegeser, J. A., Zemann, W. & Graetz, K. W. Osteopathology of the jaw associated with bone resorption inhibitors: What have we learned in the last 8 years?. Swiss Med. Wkly. 142, w13605. https:\/\/doi.org\/10.4414\/smw.2012.13605 (2012).","journal-title":"Swiss Med. Wkly."},{"key":"15720_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.oraloncology.2011.11.004","volume":"48","author":"M Schubert","year":"2012","unstructured":"Schubert, M. et al. The Saxon bisphosphonate register\u2014therapy and prevention of bisphosphonate-related osteonecrosis of the jaws. Oral Oncol. 48, 349\u2013354. https:\/\/doi.org\/10.1016\/j.oraloncology.2011.11.004 (2012).","journal-title":"Oral Oncol."},{"key":"15720_CR12","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.joms.2015.09.024","volume":"73","author":"SL Ruggiero","year":"2015","unstructured":"Ruggiero, S. L. & Kobn, N. Disease stage and mode of therapy are important determinants of treatment outcome for medicationrelated osteonecrosis of the jaw. J. Oral Maxillofac. Surg. 73, S94-100. https:\/\/doi.org\/10.1016\/j.joms.2015.09.024 (2015).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"15720_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jcms.2015.12.017","volume":"44","author":"T M\u00fccke","year":"2016","unstructured":"M\u00fccke, T. et al. The role of mylohyoid flap in the treatment of bisphosphonate-related osteonecrosis of the jaws. J. Craniomaxillofac. Surg. 44, 369\u2013373. https:\/\/doi.org\/10.1016\/j.jcms.2015.12.017 (2016).","journal-title":"J. Craniomaxillofac. Surg."},{"key":"15720_CR14","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.bjoms.2016.06.015","volume":"54","author":"M Nisi","year":"2016","unstructured":"Nisi, M. et al. Conservative surgical management of patients with bisphosphonate-related osteonecrosis of the jaws: A series of 120 patients. Br. J. Oral Maxillofac. Surg. 54, 930\u2013935. https:\/\/doi.org\/10.1016\/j.bjoms.2016.06.015 (2016).","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"15720_CR15","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.joms.2016.12.014","volume":"75","author":"HY Kim","year":"2017","unstructured":"Kim, H. Y. et al. Extensive surgical procedures result in better treatment outcomes for bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis. J. Oral Maxillofac. Surg. 75, 1404\u20131413. https:\/\/doi.org\/10.1016\/j.joms.2016.12.014 (2017).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"15720_CR16","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jcms.2017.05.027","volume":"45","author":"M Zirk","year":"2017","unstructured":"Zirk, M. et al. The impact of surgical intervention and antibiotics on MRONJ stage II and III - Retrospective study. J. Craniomaxillofac. Surg. 45, 1183\u20131189. https:\/\/doi.org\/10.1016\/j.jcms.2017.05.027 (2017).","journal-title":"J. Craniomaxillofac. Surg."},{"key":"15720_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/odi.12764","volume":"24","author":"G Favia","year":"2018","unstructured":"Favia, G., Tempesta, A., Limongelli, L., Crincoli, V. & Maiorano, E. Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment?. Oral Dis. 24, 238\u2013242. https:\/\/doi.org\/10.1111\/odi.12764 (2018).","journal-title":"Oral Dis."},{"key":"15720_CR18","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/jbmr.3191","volume":"32","author":"S Hayashida","year":"2017","unstructured":"Hayashida, S. et al. Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: A multicenter retrospective study with propensity score matching analysis. J. Bone Miner. Res. 32, 2022\u20132029. https:\/\/doi.org\/10.1002\/jbmr.3191 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"15720_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00774-019-01035-7","volume":"38","author":"S Hayashida","year":"2020","unstructured":"Hayashida, S. et al. Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. J. Bone Miner. Metab. 38, 126\u2013134. https:\/\/doi.org\/10.1007\/s00774-019-01035-7 (2020).","journal-title":"J. Bone Miner. Metab."},{"key":"15720_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5125\/jkaoms.2014.40.5.206","volume":"40","author":"YH Kim","year":"2014","unstructured":"Kim, Y. H., Lee, H. K., Song, S. I. & Lee, J. K. Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw. J. Korean Assoc. Oral Maxillofac. Surg. 40, 206\u2013210. https:\/\/doi.org\/10.5125\/jkaoms.2014.40.5.206 (2014).","journal-title":"J. Korean Assoc. Oral Maxillofac. Surg."},{"key":"15720_CR21","doi-asserted-by":"publisher","first-page":"101072","DOI":"10.1016\/j.bonr.2021.101072","volume":"14","author":"N Kaibuchi","year":"2021","unstructured":"Kaibuchi, N. et al. The progress of medication-related osteonecrosis of the jaw with conservative initial treatment: A 12-year retrospective study of 129 patients. Bone Rep. 14, 101072. https:\/\/doi.org\/10.1016\/j.bonr.2021.101072 (2021).","journal-title":"Bone Rep."},{"key":"15720_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","volume":"69","author":"S Otto","year":"2018","unstructured":"Otto, S., Pautke, C., Van den Wyngaert, T., Niepel, D. & Schi\u00f8dt, M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat. Rev. 69, 177\u2013187. https:\/\/doi.org\/10.1016\/j.ctrv.2018.06.007 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"15720_CR23","unstructured":"Totsuka, Y., Takato, T. Oral sciences 669\u2013670 (Asakura Publishing Co., Ltd., Tokyo, 2013)."},{"issue":"suppl. 3","key":"15720_CR24","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1007\/BF01623002","volume":"3","author":"BJ Gertz","year":"1993","unstructured":"Gertz, B. J., Holland, S. D., Kline, W. F., Matuszewski, B. K. & Porras, A. G. Clinical pharmacology of alendronate sodium. Osteoporos. Int. 3(suppl. 3), S13\u2013S16. https:\/\/doi.org\/10.1007\/BF01623002 (1993).","journal-title":"Osteoporos. Int."},{"key":"15720_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2147\/btt.s2082","volume":"2","author":"EM Lewiecki","year":"2008","unstructured":"Lewiecki, E. M. Denosumab: An investigational drug for the management of postmenopausal osteoporosis. Biologics 2, 645\u2013653. https:\/\/doi.org\/10.2147\/btt.s2082 (2008).","journal-title":"Biologics"},{"key":"15720_CR26","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.4317\/medoral.23324","volume":"25","author":"A Limones","year":"2020","unstructured":"Limones, A. et al. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab vs. zoledronic acid: a systematic review and meta-analysis. Med. Oral Patol. Oral Cir. Bucal 25, e326\u2013e336. https:\/\/doi.org\/10.4317\/medoral.23324 (2020).","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"15720_CR27","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s00198-017-4063-7","volume":"28","author":"T Hasegawa","year":"2017","unstructured":"Hasegawa, T. et al. Japanese Study Group of Cooperative Dentistry with Medicine (JCDM). A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?. Osteoporos. Int. 28, 2465\u20132473. https:\/\/doi.org\/10.1007\/s00198-017-4063-7 (2017).","journal-title":"Osteoporos. Int."},{"key":"15720_CR28","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00774-019-00994-1","volume":"37","author":"Y Kojima","year":"2019","unstructured":"Kojima, Y. et al. Clinical significance of periosteal reaction as a predictive factor for treatment outcome of medication-related osteonecrosis of the jaw. J. Bone Miner. Metab. 37, 913\u2013919. https:\/\/doi.org\/10.1007\/s00774-019-00994-1 (2019).","journal-title":"J. Bone Miner. Metab."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15720-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15720-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15720-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:47:41Z","timestamp":1669358861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15720-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["15720"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-15720-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"4 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11545"}}